{"id":2779,"date":"2017-02-28T05:45:00","date_gmt":"2017-02-28T05:45:00","guid":{"rendered":"http:\/\/www.irlab.se\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"},"modified":"2017-02-28T05:45:00","modified_gmt":"2017-02-28T05:45:00","slug":"forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier","status":"publish","type":"post","link":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","title":{"rendered":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier"},"content":{"rendered":"<p><span><strong>28 februari 2017&nbsp; <em><\/em>&nbsp;<\/strong><\/span><\/p>\n<p><span><strong>Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p&aring; Nasdaq First North Premier under kortnamnet &rdquo;IRLAB A&rdquo; med ISIN kod SE0009242225.<\/strong><\/span><\/p>\n<ul>\n<li><span>IRLAB har totalt 6 999 939 utest&aring;ende aktier, varav 6&nbsp;928 388 A-aktier f&ouml;rdelat p&aring; drygt 2&nbsp;500 aktie&auml;gare.<\/span><\/li>\n<li><span>Teckningskursen i den nyemission som f&ouml;ranledde listningen, och i vilken Bolaget erh&ouml;ll erforderligt antal aktie&auml;gare f&ouml;r att uppfylla spridningskravet p&aring; Nasdaq First North Premier, uppgick till 60 kr per aktie, motsvarande en v&auml;rdering av Bolaget om 420 mkr efter nyemission.<\/span><\/li>\n<li><span>Handeln av Bolagets aktier p&aring; Nasdaq First North Premier inleds idag, den 28 februari 2017, under kortnamnet &rdquo;IRLAB A&rdquo; med ISIN kod SE0009242225.<\/span><\/li>\n<\/ul>\n<p><span><strong>R&aring;dgivare<\/strong><br \/>Stockholm Corporate Finance AB har varit finansiell r&aring;dgivare och Advokatfirman Delphi i G&ouml;teborg KB legal r&aring;dgivare till IRLAB i samband med nyemissionen. Aqurat Fondkommission AB agerade som emissionsinstitut och Avanza Bank AB som s&auml;ljagent i samband med nyemissionen.<\/span><\/p>\n<p><span>FNCA Sweden AB &auml;r Bolagets Certified Adviser p&aring; First North Premier.<\/span><\/p>\n<h3><span>F&ouml;r mer information:<\/span><\/h3>\n<table border=\"0\">\n<tr>\n<td><span>Nicholas Waters, VD&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br \/><\/span><\/td>\n<td><span>Viktor Siewertz, COO<\/span><\/td>\n<\/tr>\n<tr>\n<td><span>Tel: +46&nbsp;730 75 77 01<\/span><\/td>\n<td><span>Tel: +46&nbsp;727 10 70 70<\/span><\/td>\n<\/tr>\n<tr>\n<td><span>E-post: <a href=\"mailto:viktor.siewertz@irlab.se\" target=\"_blank\">nicholas.waters@irlab.se<\/a> &nbsp;&nbsp;&nbsp;&nbsp; <\/span><\/td>\n<td><span>E-post: <a href=\"mailto:viktor.siewertz@irlab.se\" target=\"_blank\">viktor.siewertz@irlab.se<\/a><\/span><\/td>\n<\/tr>\n<\/table>\n<p><strong><span>Kort om IRLAB<\/span><span><br \/><\/span><\/strong><span>IRLAB bildades 2013 och grundar sin verksamhet p&aring; &ouml;ver 20 &aring;rs forskning som startade redan p&aring; 1990-talet, d&aring; under ledning av Nobelpristagare Professor Arvid Carlsson. IRLAB fokuserar fr&auml;mst sin forskning p&aring; neurodegenerativa sjukdomar, i synnerhet substanser f&ouml;r medicinering vid Parkinsons sjukdom och demenser, f&ouml;r vilka det i dagsl&auml;get finns ett behov av nya och f&ouml;rb&auml;ttrade behandlingsmetoder.<\/span><\/p>\n<p><span>IRLAB har tv&aring; prim&auml;ra l&auml;kemedelskandidater, IRL752 och IRL790, b&aring;da med genomf&ouml;rda Fas I-studier i friska frivilliga forskningspersoner, samt ytterligare tre projekt i preklinisk fas. IRLAB har ocks&aring; ett forskningsprogram som syftar till att ta fram l&auml;kemedelskandidater med hj&auml;lp av den unika och egenutvecklade forskningsplattformen, ISP.<\/span><\/p>\n<p><span>IRLAB &auml;r baserat i G&ouml;teborg. IRLAB:s verksamhet bedrivs huvudsakligen genom dotterbolaget Integrative Research Laboratories Sweden AB.<\/span><\/p>\n<p><span>F&ouml;r mer information, v&auml;nligen bes&ouml;k <a href=\"https:\/\/irlab.se\" target=\"_blank\">www.irlab.se<\/a><\/span><\/p>\n<p><span><strong><br \/><\/strong><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>28 februari 2017&nbsp; &nbsp; Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p&aring; Nasdaq First North Premier under kortnamnet &rdquo;IRLAB A&rdquo; med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest&aring;ende aktier, varav 6&nbsp;928 388 A-aktier f&ouml;rdelat p&aring; drygt 2&nbsp;500 aktie&auml;gare. Teckningskursen i den nyemission som f&ouml;ranledde listningen, och i vilken Bolaget [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[23],"tags":[37],"class_list":["post-2779","post","type-post","status-publish","format-standard","hentry","category-pressmeddelande-2","tag-irlab"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v26.7 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB\" \/>\n<meta property=\"og:description\" content=\"28 februari 2017&nbsp; &nbsp; Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p&aring; Nasdaq First North Premier under kortnamnet &rdquo;IRLAB A&rdquo; med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest&aring;ende aktier, varav 6&nbsp;928 388 A-aktier f&ouml;rdelat p&aring; drygt 2&nbsp;500 aktie&auml;gare. Teckningskursen i den nyemission som f&ouml;ranledde listningen, och i vilken Bolaget [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\" \/>\n<meta property=\"og:site_name\" content=\"IRLAB\" \/>\n<meta property=\"article:published_time\" content=\"2017-02-28T05:45:00+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier\",\"datePublished\":\"2017-02-28T05:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\"},\"wordCount\":410,\"commentCount\":0,\"keywords\":[\"irlab\"],\"articleSection\":[\"Pressmeddelande\"],\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\",\"url\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\",\"name\":\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB\",\"isPartOf\":{\"@id\":\"https:\/\/irlab.se\/#website\"},\"datePublished\":\"2017-02-28T05:45:00+00:00\",\"author\":{\"@id\":\"\"},\"breadcrumb\":{\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/irlab.se\/sv\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/irlab.se\/#website\",\"url\":\"https:\/\/irlab.se\/\",\"name\":\"Irlab\",\"description\":\"Novel treatments for Parkinson&#039;s disease\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/irlab.se\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","og_locale":"sv_SE","og_type":"article","og_title":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","og_description":"28 februari 2017&nbsp; &nbsp; Handeln i aktierna i IRLAB Therapeutics AB (publ) inleds idag p&aring; Nasdaq First North Premier under kortnamnet &rdquo;IRLAB A&rdquo; med ISIN kod SE0009242225. IRLAB har totalt 6 999 939 utest&aring;ende aktier, varav 6&nbsp;928 388 A-aktier f&ouml;rdelat p&aring; drygt 2&nbsp;500 aktie&auml;gare. Teckningskursen i den nyemission som f&ouml;ranledde listningen, och i vilken Bolaget [&hellip;]","og_url":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","og_site_name":"IRLAB","article_published_time":"2017-02-28T05:45:00+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#article","isPartOf":{"@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"},"author":{"name":"","@id":""},"headline":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier","datePublished":"2017-02-28T05:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"},"wordCount":410,"commentCount":0,"keywords":["irlab"],"articleSection":["Pressmeddelande"],"inLanguage":"sv-SE","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","url":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/","name":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier - IRLAB","isPartOf":{"@id":"https:\/\/irlab.se\/#website"},"datePublished":"2017-02-28T05:45:00+00:00","author":{"@id":""},"breadcrumb":{"@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/irlab.se\/sv\/forsta-handelsdag-for-irlab-therapeutics-aktier-pa-first-north-premier\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/irlab.se\/sv\/"},{"@type":"ListItem","position":2,"name":"F\u00f6rsta handelsdag f\u00f6r IRLAB Therapeutics aktier p\u00e5 First North Premier"}]},{"@type":"WebSite","@id":"https:\/\/irlab.se\/#website","url":"https:\/\/irlab.se\/","name":"Irlab","description":"Novel treatments for Parkinson&#039;s disease","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/irlab.se\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"}]}},"_links":{"self":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/comments?post=2779"}],"version-history":[{"count":0,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/posts\/2779\/revisions"}],"wp:attachment":[{"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/media?parent=2779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/categories?post=2779"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/irlab.se\/sv\/wp-json\/wp\/v2\/tags?post=2779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}